Every review,
one place.
A clean article index with active, working links. Each piece includes its evidence label, review date, source note, and medical-advice disclaimer.
Retatrutide vs. tirzepatide: evidence, mechanism, and status compared.
A source-led comparison of the investigational triple agonist retatrutide and the FDA-approved dual agonist tirzepatide, with trial maturity, outcomes, safety caveats, and availability kept separate from hype.
GHK-Cu copper peptide: the skin-repair peptide, audited.
A deep, source-backed guide to GHK-Cu / copper tripeptide-1: what it is, why skincare and peptide clinics talk about it, what human evidence exists, where the gene-expression story gets overhyped, and how to think about topical vs injectable use.
Retatrutide: the triple-agonist obesity drug everyone is watching.
A deep, source-backed guide to retatrutide, the investigational GLP-1/GIP/glucagon triple agonist, including phase 2 weight-loss data, diabetes results, liver-fat signals, safety questions, and why access hype is premature.
Sermorelin peptide therapy: what the evidence can actually support.
A deep, source-backed guide to sermorelin, growth-hormone signaling, FDA history, longevity-clinic claims, safety questions, and where the anti-aging pitch outruns human outcomes data.
NAD+, NR, NMN, and IV NAD therapy: where the science ends and the hype begins.
A deep guide to NAD+ biology, oral precursors, IV drips, supplement claims, clinical evidence, safety questions, and why raising a biomarker is not the same as reversing aging.
What to ask your clinician before starting a GLP-1 medicine.
A practical, source-backed checklist for discussing semaglutide, tirzepatide, compounded products, monitoring, side effects, pregnancy planning, cost, and long-term maintenance without turning the visit into an internet protocol.
Retatrutide and “anti-aging” peptides: what the evidence can actually support.
A source-backed review of a viral retatrutide, GHK-Cu, and MOTS-c video: where the biology is plausible, where human data exists, and where the claims outrun the evidence.
Orforglipron and the oral GLP-1 watchlist.
Why a daily pill could change the GLP-1 market — and why convenience still does not answer efficacy, safety, access, and maintenance questions.
Amycretin, CagriSema, and the amylin moment.
The next metabolic medicine story may be less about one receptor and more about multi-pathway satiety signals.
The maintenance plan after GLP-1 weight loss.
Plateaus, protein, resistance training, coverage loss, dose changes, and the question everyone postpones: what happens if you stop?
The MASH-obesity crossover: mazdutide, pemvidutide, survodutide.
Why metabolic therapy is spilling into liver disease headlines, and how to avoid mixing up weight-loss, liver-fat, and MASH endpoints.
Tirzepatide, after the hype.
The uncomfortable parts of the GLP-1 boom that rarely make it into glossy before-and-afters: tolerance, muscle retention, cost, access, and what happens when treatment stops.
Semaglutide vs. Tirzepatide: a 36-week head-to-head.
Mean BMI loss, lean-mass preservation, lipid panels and the side-effect curve nobody charts honestly.
Epitalon: the longevity peptide that won't quit the headlines.
Old research, modern protocols, and why telomere language can sound more settled than the evidence actually is.
Polynucleotide salmon DNA injectables, audited.
What early dermatology data and patient photos suggest: texture looks more plausible than lift, and the word “regenerative” needs a haircut.
The case for early HRT — and the studies that quietly buried the WHI.
Timing, symptom burden, bone density, risk stratification, and why menopause medicine still argues with a 2002 headline.
CJC-1295 / Ipamorelin: the growth-hormone stack, demystified.
Recovery claims, sleep anecdotes, glucose tradeoffs, and why the protocol matters more than the peptide-shop sales page.
Tretinoin at 0.025%, every other night, for ten years.
The boring skincare active that still beats most launches — if your barrier survives the onboarding period.